Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1239
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Alabama at Birmingham, Birmingham, AL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Alabama at Birmingham, Birmingham, AL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 853–864 of 1,239 matching trials with a site at University of Alabama at Birmingham, Birmingham, AL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional Results available

Serial Assessment of Body Fat Accrual in Very Preterm Infants

NCT03575897
Site status not listed — check the official record
View directory record Official record
Conditions
Infant,Premature, Body Weight, Adiposity
Interventions
Assessment of infant body composition
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 14 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Recruiting Phase 1 Interventional

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

NCT02074839
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Interventions
AG-120
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Active, not recruiting Phase 1 Interventional

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

NCT04323046
Site status not listed — check the official record
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
Interventions
Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
6 Months to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

NCT05164341
Site status not listed — check the official record
View directory record Official record
Conditions
Partial Lipodystrophy
Interventions
metreleptin, Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
12 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Sacramento, California • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Recruiting Not applicable Interventional

Radiation Free Study

NCT06549348
Status at this site: Recruiting
View directory record Official record
Conditions
Aortic Aneurysm
Interventions
Measure average procedure fluoroscopy time using LumiGuide and conventional fluoroscopy guidance
Radiation
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Recruiting Phase 2 Interventional

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

NCT07521137
Status at this site: Recruiting
View directory record Official record
Conditions
Candidiasis, Vulvovaginal
Interventions
OCF001 Intravaginal Gel, Placebo Gel
Drug
Lead sponsor
Sano Chemicals Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Active, not recruiting Phase 3 Interventional

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

NCT04457596
Site status not listed — check the official record
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
Interventions
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
1160
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Recruiting Phase 2 Interventional

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

NCT06364917
Status at this site: Recruiting
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Process-Based Approach Case Series For Anxiety Problems

NCT07352592
Status at this site: Recruiting
View directory record Official record
Conditions
Anxiety
Interventions
Process-Based Approach
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Active, not recruiting Phase 3 Interventional

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

NCT04333576
Site status not listed — check the official record
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix, Placebo, Combined Oral Contraceptive
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
176
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Active, not recruiting No phase listed Observational

REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

NCT05611918
Site status not listed — check the official record
View directory record Official record
Conditions
Intra Cerebral Hemorrhage, ICH - Intracerebral Hemorrhage, ICH, Hemorrhage, Stroke, Clot (Blood); Brain, Clot Blood, Cognitive Decline, Cognitive Impairment, Survivorship, Memory Impairment, Motor Activity
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 7, 2026, 11:14 AM EST
Recruiting No phase listed Observational

Histiocytic Disorder Follow-up Study

NCT05915208
Status at this site: Recruiting
View directory record Official record
Conditions
Histiocytosis, Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai Dorfman Disease, Xanthogranuloma, Malignant Histiocytoses
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
0 Years to 89 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 7, 2026, 11:14 AM EST

About this University of Alabama at Birmingham institution page

What this page lists
ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.